New Delhi [India], September 23: Lord's Mark Industries Limited has informed the BSE that its Technical Committee has approved the final clinical trial stage for its AI-powered, radiation-free wearable breast cancer screening device , with trials planned across the USA, Great Britain and Europe . The disclosure was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015 .
The device, developed in collaboration with the Centre for Materials for Electronic Technology (C-MET) , uses thermal sensors and AI-based temperature mapping to identify abnormalities without radiation. According to the company, clinical trials in India have been completed, with Phase 2 trials targeting cell-level detection accuracy of 98% set to begin from January 2027 across India, the USA, Europe and Great Britain .
Lord's Mark holds exclusive commercialisation rights for the technology . The company said it is targeting completion of final trials and key regulatory milestones before March 2027 , with commercial launch envisaged by April 2027 - both subject to clinical outcomes and regulatory approvals. Regulatory evaluation in India is ongoing, with CDSCO approval in process ; the company said it is also pursuing conformity requirements in Europe and FDA pathways in the US .
Separately, the company noted it has made representations to relevant authorities seeking the technology's inclusion in national breast cancer screening programmes , and to IRDAI for possible insurance coverage consideration .
Published by HT Digital Content Services with permission from PNN.